Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wan, Chao ^a   Sun, Jianping ^a   Chen, Weizao ^b   Yuan, Xiaohui ^a   Chong, Huihui ^a   Prabakaran, Ponraj ^b   Dimitrov, Dimiter S ^b   He, Yuxian ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GLYCOPROTEIN GP 120; M36; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR DOCKING; NONHUMAN; PREDICTION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS;

ANTIBODIES, NEUTRALIZING; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84878866131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066638     Document Type: Article

References (43)

1. Este JA, Telenti A, (2007) HIV entry inhibitors. Lancet 370: 81-88.
2. Fauci AS, (2008) 25 years of HIV. Nature 453: 289-290.
3. Chen W, Dimitrov DS, (2012) Monoclonal antibody-based candidate therapeutics against HIV type 1. AIDS Res Hum Retroviruses 28: 425-434.
4. Gong R, Chen W, Dimitrov DS, (2012) Candidate antibody-based therapeutics against HIV-1. BioDrugs 26: 143-162.
5. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77: 10557-10565.
6. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
7. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, et al. (2005) Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 11: 615-622.
8. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, et al. (2002) A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16: 227-233.
9. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9: 343-346.
10. Wu X, Yang ZY, Li Y, Hogerkorp CM, (2010) Schief WR, et al (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
11. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
12. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
13. Gorlani A, Brouwers J, McConville C, van der Bijl P, Malcolm K, et al. (2012) Llama antibody fragments have good potential for application as HIV type 1 topical microbicides. AIDS Res Hum Retroviruses 28: 198-205.
14. McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman MS, et al. (2012) Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J Exp Med 209: 1091-1103.
15. Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, et al. (2008) Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 82: 12069-12081.
16. Chen W, Dimitrov DS, (2009) Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 4: 112-117.
17. Chen W, Feng Y, Wang Y, Zhu Z, Dimitrov DS, (2012) Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies. Biochem Biophys Res Commun 425: 931-937.
18. Chen W, Zhu Z, Feng Y, Dimitrov DS, (2008) Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A 105: 17121-17126.
19. Meyerson JR, Tran EE, Kuybeda O, Chen W, Dimitrov DS, et al. (2013) Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives. Proc Natl Acad Sci U S A 110: 513-518.
20. Cao Z, Meng J, Li X, Wu R, Huang Y, et al. (2012) The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus. PLoS One 7: e38126.
21. Bublil EM, Yeger-Azuz S, Gershoni JM, (2006) Computational prediction of the cross-reactive neutralizing epitope corresponding to the [corrected] monclonal [corrected] antibody b12 specific for HIV-1 gp120. FASEB J 20: 1762-1774.
22. Tarnovitski N, Matthews LJ, Sui J, Gershoni JM, Marasco WA, (2006) Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol 359: 190-201.
23. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
24. Eckert DM, Kim PS, (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
25. Chan DC, Kim PS, (1998) HIV entry and its inhibition. Cell 93: 681-684.
26. Berger EA, (1998) And the best picture is--the HIV gp120 envelope, please! Nat Struct Biol. 5: 671-674.
27. Chan DC, Fass D, Berger JM, Kim PS, (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
28. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC, (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
29. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326: 1123-1127.
30. Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5: e8805.
31. Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, et al. (2004) Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 78: 9233-9242.
32. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, et al. (2002) Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A 99: 6913-6918.
33. Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, et al. (2011) Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A 108: 11440-11445.
34. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113.
35. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, et al. (2012) Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog 8: e1002797.
36. White TA, Bartesaghi A, Borgnia MJ, de la Cruz MJ, Nandwani R, et al. (2011) Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography. J Virol 85: 12114-12123.
37. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al. (2010) Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog 6: e1001249.
38. Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, et al. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441: 847-852.
39. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, et al. (2004) Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 43: 1410-1417.
40. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS, (2010) Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 88: 107-115.
41. Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A, et al. (2007) Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins 68: 294-304.
42. Mayrose I, Penn O, Erez E, Rubinstein ND, Shlomi T, et al. (2007) Pepitope: epitope mapping from affinity-selected peptides. Bioinformatics 23: 3244-3246.
43. Rose PW, Bi C, Bluhm WF, Christie CH, Dimitropoulos D, et al. (2013) The RCSB Protein Data Bank: new resources for research and education. Nucleic Acids Res 41: D475-482.